Entries |
Document | Title | Date |
20080206789 | Method of Screening Mhc Molecules - The invention relates to a method for screening the binding properties of constituent peptides of MHC molecules by providing in solution MHC molecules or their constituent peptides for a set of MHC molecules including a plurality of subsets of MHC molecules, wherein the MHC molecules of each subset differ from MHC molecules of at least one other subset in at least one of the putative MHC binding peptide, an MHC alpha chain and an MHC beta chain, and loading said MHC molecules with an MHC binding peptide by (i) refolding of the MHC alpha chain and beta chain peptides in presence of said MHC binding peptide or (ii) by peptide exchange or loading with an unlabelled MHC binding peptide in the absence of any labelled MHC binding peptide, (b) taking of at least one sample from each subset, and (c) determining loading efficiency for the sample of step (b). | 08-28-2008 |
20080206790 | Assay for determining the presence or amount of newly synthesized antibodies - The present invention provides a method of determining the presence or amount of newly synthesised antibody in a sample in response to an immunogen by detecting the released antibodies or parts thereof in a sample containing lymphocytes which have been disrupted whereby to release the synthesised antibodies or parts thereof associated with said lymphocytes whereby to determine the presence or amount of newly synthesised antibody in said sample, methods of diagnosis using said method and kits for performing the method. The method may also be modified to allow detection of non-specific infection indicators. | 08-28-2008 |
20080227123 | Methods for Specifically Selecting Antibody-Producing Cells - Methods are provided for selecting B cells that produce a desired antibody, comprising a step of culturing B cells, which have the properties of cell death being induced under specific conditions and that cell death being suppressed by a signal generated as a result of the binding between an antigen and an antibody expressed on B cell surface (B cell antigen receptor on the B cell surface), with an antigen under conditions in which cell death is induced, and selecting antibody-producing B cells that bind with the antigen as viable cells. | 09-18-2008 |
20080233599 | IMMUNOGENIC GLYCOPEPTIDES, SCREENING, PREPARATION AND USES - The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and preparing them. Said glycopeptides are selected in the group consisting of: a1) glycopeptides essentially consisting of a glycosylated T epitope, comprising 14 to 25 amino acids, among which at least a neutral amino acid is bound to a di- or to a trisaccharide (glycoside linkage) and at least 15% among said amino acids are proline, one of the proline being located in position −1 to −4, relative to the position of said neutral amino acid, which glycopeptides are: exhibited by a class II MHC molecule, specifically identified by T CD+4 lymphocytes induced by immunisation with the native glycopeptide from which they are derived, but are not identified by the T CD+4 lymphocytes induced by immunisation with a non-glycosylated peptide of same sequence and capable of inducing a proliferation of said T CD+4 lymphocytes by which they are identified and the secretion of cytokines by said lymphocytes and b1) glycopeptides having a sequence of 15 to 39 amino acids including the sequence of the glycopeptide as defined in a1), excluding the glycopeptide of sequence SEQ ID NO:11. | 09-25-2008 |
20080248502 | Methods For Detecting Th1 Cells - The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases. | 10-09-2008 |
20080248503 | Methods of Screening Compounds to Predict Toxicity and Residual Proliferative and Differentiation Capacity of the Lympho-Hematopoietic System - The present invention relates generally to kits that provide reagent mixes and instructions for the use thereof, in performing high-throughput assay methods that provide a method of screening compounds for cytotoxicity or other effects on target cell populations of the lymphohematopoietic system, including specific lineages. The methods measure the luminescent output derived from the intracellular ATP content of incubated target cells, and correlate the luminescence with the proliferative status of the cells. The methods may be used to predict the effect of virtually any compound on the lymphohematopoietic system and may be performed on multiple species simultaneously, thereby providing valuable information regarding potential cytotoxicity prior to preclinical studies and especially, patient clinical trials. The methods also provide the ability to screen compounds early in the drug development profile. | 10-09-2008 |
20080268474 | PRION PROTEIN LIGANDS AND METHODS OF USE - Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject | 10-30-2008 |
20080305503 | Diagnostic Test - The invention provides a method of diagnosing | 12-11-2008 |
20090017475 | Method to Determine Pseudo-Allergic Reactions - Method and kit for determining the possible appearance of adverse reactions (such as anaphylactoid reactions) in patients in need to undergo to an administration of a pharmaceutical compound. The method for determining potential hypersensitivity in a patient to pseudo-allergic reactions comprises adding a predetermined amount of a compound with anaphylatoxic activity to a sample of the patient's blood and determining the amount of activation of the patient's basophil cells in said blood sample. The compound with anaphylatoxic activity is preferably selected from C3a, C5a, analogs of C3a or C5a, derivatives of C3a or C5a, and mixtures thereof. | 01-15-2009 |
20090023161 | STRUCTURAL BASIS FOR TARGETING HIV-1 GAG PROTEINS TO THE PLASMA MEMBRANE FOR VIRUS ASSEMBLY - The present invention provides for testing methods to determine an effective testing agent that affects the activity of the HIV Gag protein at the plasma membrane of a cell, and specifically, effecting changes in the structural conformation of at least one fatty acid of PI(4,5)P | 01-22-2009 |
20090029394 | Novel Assay for the Detection of an Antibody Bound to a Cell Membrane Receptor - This invention relates to the design of a novel immunoassay specific for the measurement of humanized antibody, Campath-1H, bound to the CD52 cell membrane receptor. The method can be used for pharmacokinetic studies and for monitoring purposes. The invention reveals improvements in higher specificities and sensitivities that can be obtained in relation to the conventionally used methods. | 01-29-2009 |
20090047690 | Method of analyzing white blood cells - The invention provides methods and compositions for identifying and counting lymphocytes in a biological sample, such as whole blood, by means of a probe comprising at least one binding compound specific for a T lymphocyte-specific marker, e.g. a CD2 or CD3, and at least one binding compound specific for CD45RA. Lymphocytes within the sample combine with such a probe to form a distinguishable subpopulation based on the amount of probe that specifically binds to their surfaces, thereby permitting such lymphocytes to be detected and enumerated on the basis of the intensity of the signal generated by the probe, and without the need of a separate physical measurement, such as light scatter. With additional probes specific for additional blood cell markers, percentages of lymphocytes, monocytes and granulocytes in a sample may be determined. | 02-19-2009 |
20090061463 | P-Selectin associated with Eosinophils as a marker for asthma and correlating with B-1 integrin activation - Methods are provided for the detection of P-selectin associated with eosinophils and for the use of P-selectin as a biological marker for asthma. In one embodiment, the present invention relates to methods for detecting P-selectin in a sample containing eosinophils and quantifying the total number of eosinophils. In another embodiment, the present invention relates a method for determining the proportion of eosinophils that are P-selectin positive and positive for at least partially activated β-1 integrin. In yet another embodiment, the present invention relates to kits for the detection of P-selectin and for the detection of eosinophils that are both P-selectin positive and positive for at least partially activated β-1 integrin. In still yet another embodiment, the invention relates to a method for monitoring a biological condition. | 03-05-2009 |
20090068686 | Method for diagnosing auto-immune chronic urticaria - In certain embodiments, the present invention relates to methods, compositions, and kits for diagnosing autoimmune chronic urticaria. For example, in certain embodiments, such methods generally comprise detecting the presence of auto-antibodies to cell-surface IgE receptors or cell-bound IgE in a patient. Such auto-antibodies may be detected by (a) obtaining donor basophils and associated leukocytes from one or more donors, (b) challenging the donor basophils and associated leukocytes with control serum and quantifying the amount of histamine released by the donor basophils and associated leukocytes, (c) calculating a normalized baseline of histamine release, wherein the normalized baseline of histamine release represents a mean percentage of histamine released by the basophils and associated leukocytes of an individual donor plus a specified amount above such mean, (d) reacting patient serum with the donor basophils and associated leukocytes, (e) measuring the percentage of histamine released by the donor basophils and associated leukocytes in response to the patient serum, and (f) comparing the percentage of histamine released by the donor basophils and associated leukocytes in response to the patient serum to the normalized baseline of histamine release. | 03-12-2009 |
20090075303 | Allo and Auto-Reactive T-Cell Epitopes - The present invention relates to a pharmaceutical composition for the prevention of alloimmunisation of a subject or the immunosuppression of a response elicited by alloimmunisation of a subject or an autoimmune haemolytic disease for said composition comprising an immunologically effective epitope of a rhesus protein or an immunologically active analogue or derivative thereof. | 03-19-2009 |
20090075304 | METHODS OF ASSAYING VACCINE POTENCY - The present invention is related to methods of assaying potency of a vaccine composition, wherein the potency is a pre-defined minimum level of potential biological activity for the vaccine composition. The method includes providing a vaccine composition and delivering same to an antigen presenting cell, wherein the vaccine composition is processed into peptides and the peptides are presented by MHC complexes on the cell surface. An agent, such as a T cell receptor mimic, that is reactive against a specific peptide/MHC complex is provided and reacted with the vaccine-treated antigen presenting cell, whereby the agent binds to the cell surface of the vaccine-treated antigen presenting cell if the specific peptide/MHC complex recognized by the agent is present on the cell surface. A density of the specific peptide/MHC complex on the surface of the vaccine-treated antigen presenting cell is measured by agent binding. The potency of the vaccine is then determined based upon the measured density of specific peptide/MHC complex present on the surface of the vaccine-treated antigen presenting cell. | 03-19-2009 |
20090111128 | METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES - Tumor necrosis factor (TNF) is capable of inducing apoptosis by interacting with specific TNF receptors on the surface of cancer cells. Because multiple members of TNF ligand and receptor are present within each superfamily, over 300 different ligand-receptor combinations exist. Activated blood leukocytes produce TNF as part of the immune response to cancer, as well as producing chemokines to attract other leukocytes to the site. A method is disclosed of detecting significant induction of a variety of TNF superfamily subtype and chemokine mRNAs in blood leukocytes when whole blood is exposed to heat-aggregated IgG or anti-T cell receptor antibodies as a model of immune system interactions. Substantial individual-to-individual variation is observed in TNF subtypes and chemokines induced. Since peripheral blood leukocytes are the supply of anti-cancer immune cells, the quantitation of ex vivo inducibility of appropriate TNF ligands and chemokines in blood will be useful in individualized cancer immunotherapy. If the tumor mass is small, such as with early invisible metastatic lesions, appropriate TNF assaults may be sufficient to prevent relapse. | 04-30-2009 |
20090148869 | CELL ASSAY KIT AND METHOD - A method and kit for assaying a cell sample for the presence of at least a threshold number of cells of a given type are disclosed. The kit includes an assay device having a sample chamber for receiving the cell sample and an elongate collection chamber containing a selected-density and/or viscosity medium and having along its length, a plurality of cell-collection regions, and particles which are capable of specific attachment to cells of the selected cell type, and which are effective, when attached to the cells, to increase the density or magnetic susceptibility of the cells. In operation, particle-bound cells and particles in the cell sample are drawn through the elongate collection chamber under the influence of a gravitational or selected centrifugal or magnetic-field force until the particle-bound cells and particles completely fill successive cell-collection regions in the collection chamber. Indicia associated with at least one collection regions indicates a concentration of cells of the selected type effective to at least partially fill that collection region. | 06-11-2009 |
20090176255 | IMMUNOMAGNETIC CAPTURE AND IMAGING OF BIOLOGICAL TARGETS - The present invention relates to methods and systems for labeling, isolating, detecting, and/or enumerating a statistically significant number of biological cells, or other biological analytes of interest, present in a complex matrix sample. The isolation of a biological target of interest from a sample mixture is done by immunomagnetic separation. Upon introduction of the sample within an imaging chamber, the capture complex (biological target-magnetic capture agent) will be attracted by the magnetic field and will lay on the surface of the chamber in the focal plane of the imaging system. | 07-09-2009 |
20090221005 | METHOD FOR DETECTING ANTIGEN SPECIFIC OR MITOGEN-ACTIVATED T CELLS - The present invention comprises a method for the quantitative or qualitative detection of antigen-specific CD4+ T cells and/or CD8+ T cells in a subject, said method comprising quantitatively or qualitatively detecting the expression of cell surface marker CD25 and one or more of cell surface markers CD134 and CD137 in a suitable lymphocyte-containing sample from said subject in response to exposure to an antigen. A method for determining the immunocompetence of a subject and a method for isolating antigen-specific CD4+ and/or CD8+ T cells is also disclosed. | 09-03-2009 |
20090233318 | Methods of assaying vaccine potency - The present invention is related to methods of assaying potency of a vaccine composition, wherein the potency is a pre-defined minimum level of potential biological activity for the vaccine composition. The method includes providing a vaccine composition and delivering same to an antigen presenting cell, wherein the vaccine composition is processed into peptides and the peptides are presented by MHC complexes on the cell surface. An agent, such as a T cell receptor mimic, that is reactive against a specific peptide/MHC complex is provided and reacted with the vaccine-treated antigen presenting cell, whereby the agent binds to the cell surface of the vaccine-treated antigen presenting cell if the specific peptide/MHC complex recognized by the agent is present on the cell surface. A density of the specific peptide/MHC complex on the surface of the vaccine-treated antigen presenting cell is measured by agent binding. The potency of the vaccine is then determined based upon the measured density of specific peptide/MHC complex present on the surface of the vaccine-treated antigen presenting cell. | 09-17-2009 |
20090246805 | METHOD FOR CLASSIFYING AND COUNTING BASOPHILS - A method for counting basophils which comprises: (1) mixing and reacting a blood sample with an anti-CD123 antibody labeled with a first fluorescent label and an anti-CD294 antibody labeled with a second fluorescent label to prepare a measurement sample, (2) introducing the measurement sample into a flow cell of a flow cytometer and irradiating, with light, cells in the measurement sample flowing in the flow cell, (3) detecting fluorescences from the first and second fluorescent labels as well as two scattered lights different in angle, emitted from the cells, (4) identifying basophils on the basis of the detected fluorescences from the first and second fluorescent labels as well as the two scattered lights different in angle, and (5) counting the identified basophils. A kit for measuring basophils which comprises a CD123 antibody labeled with a first fluorescent label and a CD294 antibody labeled with a second fluorescent label. | 10-01-2009 |
20090291459 | HYBRIDOMA CAPABLE OF PRODUCING ANTI-DECTIN-1 MONOCLONAL ANTIBODY - A hybridoma capable of producing a monoclonal antibody against dectin-1, and a monoclonal antibody which specifically reacts with dectin-1. | 11-26-2009 |
20100015643 | METHOD OF QUANTITATIVE DETERMINATION OF ANTIGEN PROTEIN AND QUANTITATIVE DETERMINATION KIT THEREFOR - There is provided a method of quantitative determination using a flow cytometer, with which quantitative determination of cell surface protein can be effected more accurately than with current methods. The inventors have achieved the present invention by providing a method of quantitative determination of sites, per cell of a test sample, at which an antibody is bound to an antigen protein (sites/cell), characterized by preparing a calibration curve on the basis of fluorescent intensities obtained through measuring with a flow cytometer the amount of labeled antibodies against antigen protein which are bound to two or more groups of beads carrying known and different amounts of the antigen protein, and numeric values of the known amounts of the antigen protein, and further by measuring, with the flow cytometer, labeled antibodies against antigen protein after they have been reacted with test cells derived from a blood sample of a test subject, whereby digitalization is effected through comparison and conversion between the calibration curve and a fluorescence intensity obtained. | 01-21-2010 |
20100035282 | USE OF COMMON GAMMA CHAIN CYTOKINES FOR THE VISUALIZATION, ISOLATION AND GENETIC MODIFICATION OF MEMORY T LYMPHOCYTES - It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed. | 02-11-2010 |
20100035283 | Preparation Method - A method of performing an immunologic evaluation of a subject, comprising collecting a whole blood sample from the subject, maintaining the sample for at least 6 hours after the collection, purifying a population of cells comprising lymphocytes and antigen presenting cells from the maintained sample, optionally by a process incorporating a positive or negative affinity selection step, and using the purified cells in a cell-mediated immunoassay (CMI assay). | 02-11-2010 |
20100041075 | Tuberculosis Diagnostic Test - A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided. | 02-18-2010 |
20100055720 | USE OF THE 4-lBB RECEPTOR FOR IDENTIFYING AND/OR SEPARATING ACTIVATED REGULATORY TH CELLS (TREG) - The invention relates to the use of the 4-1BB receptor for identifying and/or separating specific regulatory Th cells after activation with an antigen, polyclonal regulatory Th cells after polyclonal activation and to a method for the identification and/or separation of regulatory Th cells, the regulatory T cells being detected on the basis of the expression of the 4-1BB receptor by an antibody, an antigen or ligands which are coupled to a fluorescent substance, haptenes or magnetic microparticles. The invention also relates to a kit comprising an antibody, an antigen or ligands for detecting the 4-1BB receptor for the identification and/or separation of a regulatory Th cell, the antibody being coupled to a fluorescent substance, haptenes or magnetic microparticles. | 03-04-2010 |
20100068734 | NANOPARTICLE AND MICROPARTICLE BASED DETECTION OF CELLULAR PRODUCTS - Embodiments of the present invention relate to devices and methods for detecting cellular products using detection particles having product-specific detection reagents and having a characteristic spectral feature. In particular, devices and methods are provided for measuring secreted cellular products including cytokines. Detection substrates, include microwells having product-specific capture reagents thereon or comprising hydrophobic membranes are described having greater capability to detect products from individual cells in a mixture of heterogeneous cells. With the use of multiple detection particles, multiple cellular products can be detected in a single well. Additionally, using the inherent spectral properties of detection particles, no enzymatic reactions are needed to visualize a secreted product, thereby increasing the sensitivity, reproducibility and ease of use. | 03-18-2010 |
20100086950 | IP-10 BASED IMMUNOLOGICAL MONITORING - The present invention relates to an immunological method and, more particularly, a method for measuring cell-mediated immune reactivity (CMI) in mammals based on the production of IP-10. The invention further discloses an assay and a kit for measuring CMI to an antigen using whole blood or other suitable biological samples. The methods of the present invention are useful in therapeutic and diagnostic protocols for human, livestock and veterinary and wild life applications, thus the invention further relates to a method for diagnosing an infection in a mammal. | 04-08-2010 |
20100086951 | Pan-Kinase Activation and Evaluation of Signaling Pathways - Methods and reagents are provided for determining the activation state of a signal transduction pathway signaling protein. There exists a need in the art for methods that can monitor the efficacy of a signal transduction inhibitor in a patient. Other needs exist for detecting and monitoring certain disease or disorders that are associated with aberrant activation of a signal transduction pathway signaling protein. The present assay provides a highly sensitive assay that is also useful in patient populations in which obtaining a large cellular sample is difficult, for example, neonates. | 04-08-2010 |
20100093004 | Autophagy and phospholipidosis pathway assays - Provided are assays useful for detecting and monitoring autophagy and phospholipidosis, including the progression of lysosomal storage diseases. Drugs and treatments for lysosomal storage diseases can be monitored for effectiveness in lysosomal storage disease conditions. Drug candidates and suspected toxic agents can also be screened for toxicity to cells, tissues and organs. Also provided are methods for distinguishing between phospholipidosis activators and autophagy pathway perturbation agents. | 04-15-2010 |
20100167317 | PROCESS FOR ENRICHING BASOPHILS IN A BLOOD SAMPLE - The present invention is based on the discovery that contrary to prior studies CD16 is expressed by basophils and as such provide methods and kits for enriching basophils in a blood sample. | 07-01-2010 |
20100203557 | MONOCYTE ACTIVATION TEST BETTER ABLE TO DETECT NON-ENDOTOXIN PYROGENIC CONTAMINANTS IN MEDIAL PRODUCTS - An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample. | 08-12-2010 |
20100216170 | METHODS FOR IDENTIFYING IMMUNOBINDERS OF CELL-SURFACE ANTIGENS - The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods. | 08-26-2010 |
20100221755 | USE OF ANTIBODY SECRETING CELL ELISPOT TO ASSESS ANTIBODY RESPONSES FOLLOWING ANTIGEN EXPOSURE - Disclosed are methods and kits for early detection of antigen exposure through the presence or absence of antigen-specific antibodies. | 09-02-2010 |
20100221756 | ALLERGY TEST BASED ON FLOW CYTOMETRIC ANALYSIS - The invention pertains to a method for the determination of basophil activation induced by a test substance by flow cytometric measurement of the changes of the mean or median fluorescence intensities (WI) of the basophilic F | 09-02-2010 |
20100233734 | PASSIVATION OF SURFACES AFTER LIGAND COUPLING - Passivated substrates are provided for use in assays, comprising at least one covalently bonded ligand having specific binding activity for a molecule, and at least one covalently bonded blocking agent, wherein said ligand is directly bonded to the substrate surface. In certain embodiments, the ligand and blocking agent are covalently bonded only to the substrate surface, and not directly bonded to each other. In certain other embodiments, the ligand and blocking agent have at least one additional covalent bond to one another. Methods for preparing and using passivated substrates in bioassays are also provided. | 09-16-2010 |
20100255507 | ANTIBODIES AND OTHER LIGANDS DIRECTED AGAINST KIR2DL4 RECEPTOR FOR PRODUCTION OF INTERFERON GAMMA - The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC. | 10-07-2010 |
20100255508 | USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS - The present invention is directed to methods of using biomarkers to assess treatment of gastrointestinal inflammatory disorders with beta7 antagonists. More particularly, the present invention relates to methods of using the level of gut-homing lymphocytes in peripheral blood, the level of drug occupancy on gut-homing lymphocytes, and/or the level of beta7 integrin receptors on gut-homing lymphocytes as indicators (or biomarkers) of the effect, efficacy, safety, prognosis, and/or dosing of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal inflammatory disorders. | 10-07-2010 |
20100267059 | IMMUNODEFICIENCY SCREENING AT POINT OF CARE - Embodiments of the invention utilizes advanced detection methodologies as a cost-effective, efficient, ultra-sensitive rapid method for diagnosing severe combined immunodeficiency (SCID) in infants. In certain aspects, multiple markers of SCID are concurrently detected and measured to provide a more efficient, sensitive and accurate diagnosis of SCID. | 10-21-2010 |
20100279324 | Assay For Detecting Mycobacterial Infection - Methods for assessing a mycobacterial infection in a subject comprise exposing at least one CD1 molecule or analogue to mycolic acid or a mycolic acid analogue, subsequently incubating the at least one CD1 molecule or analogue with a sample comprising at least one T cell isolated from the subject, and measuring the T cell response and/or the number of mycolic acid specific T cells present in the T cell sample. | 11-04-2010 |
20100291595 | BLOOD MONOCYTE CD163 EXPRESSION AS A BIOMARKER IN HIV-1 INFECTION AND NEUROAIDS - The invention provides a method for detecting CD163+/CD16+ cell population in peripheral blood mononuclear cells in a biological sample from a subject infected with HIV-1 which comprises contacting the biological sample with an anti-CD163 antibody, so that levels of CD163+/CD16+ peripheral blood mononuclear cells in the biological sample can be quantified. The method of the present invention is particularly useful for monitoring the course of HIV-1 infection and/or HIV Encephalopathy | 11-18-2010 |
20100297676 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of a cell present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. | 11-25-2010 |
20100311085 | CELL ASSAY KIT AND METHOD - A method and kit for assaying a cell sample for the presence of at least a threshold number of cells of a given type are disclosed. The kit includes an assay device having a sample chamber for receiving the cell sample and an elongate collection chamber containing a selected-density and/or viscosity medium and having along its length, a plurality of cell-collection regions, and particles which are capable of specific attachment to cells of the selected cell type, and which are effective, when attached to the cells, to increase the density or magnetic susceptibility of the cells. In operation, particle-bound cells and particles in the cell sample are drawn through the elongate collection chamber under the influence of a gravitational or selected centrifugal or magnetic-field force until the particle-bound cells and particles completely fill successive cell-collection regions in the collection chamber. Indicia associated with at least one collection regions indicates a concentration of cells of the selected type effective to at least partially fill that collection region. | 12-09-2010 |
20100317036 | Mycobacterium Antigens - There is provided a diagnostic reagent for use in the detection of | 12-16-2010 |
20100323371 | STROMAL INTERACTING MOLECULE KNOCKOUT MOUSE AND USES THEREOF - This invention relates to knockout mice for the Ca | 12-23-2010 |
20110045503 | The Use of Novel Coumarins as Glutathione and Thiol Labels - Fluorescent quinolizinocoumarin compounds substituted with electrophilic reactive groups that bind thiol compounds are described. The compounds are useful in detecting oxidative stress and processes associated therewith in live cells. | 02-24-2011 |
20110053186 | Chlorite in the Treatment of Neurodegenerative Disease - The invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation. The invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy. | 03-03-2011 |
20110059471 | ANTIBODY HAVING AN IMMUNE-ENHANCEMENT FUNCTION - The present invention provides a monoclonal antibody against FLJ32028, which binds specifically to the surfaces of regulatory T-cells (Treg) and especially to the surfaces of induced Treg. This monoclonal antibody can be used for a Treg-removal method or a Treg-removal apparatus. This monoclonal antibody can also be used as a drug that improves cell-proliferation function, an immune-enhancement function, or especially for cancer treatment. | 03-10-2011 |
20110065131 | ASSAYS FOR MUTAGENESIS DETECTION - The disclosure provides methods, systems, and kits for assaying an agent for mutagenic properties. The methods systems and kits utilize a DEL selectable marker and a colorimetric detection systems. Also included are methods systems and kits that utilize a DEL selectable marker and a regent that detects mitochondrial activity. | 03-17-2011 |
20110070599 | Method for Screening of Active Tuberculosis - The present invention provides an improved and simplified assay for use in diagnosing active Tuberculosis infections. The present assay is carried out using a sample of whole blood, does not require separating the blood into components, such as the isolation of peripheral blood mononucleocytes (PBMC), and is carried out using only cell-surface staining of T-cells. | 03-24-2011 |
20110081666 | ANTI-PSGL-1 INHIBITORS AND SCREENING METHODS - The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for inhibitory compounds including such antibodies and binding fragments thereof and to methods of therapeutic use thereof. | 04-07-2011 |
20110086367 | PHARMACEUTICALS FOR INFLUENCING THE REACTION OF THE HUMAN IMMUNE SYSTEM - The present invention uses the potency and efficacy of human glycoprotein-A repetitions predominant protein (GARP), the gene of which is located on chromosome 11q13-11q14 in the reprogramming of antigen-specific effector T-helper cells, which are CD4 | 04-14-2011 |
20110086368 | METHOD FOR IMMUNE RESPONSE DETECTION - A method for detecting one or more immunological response factors that is expressed in response to a therapeutic treatment and/or disease using a piezoelectric microcantilever sensor (PEMS) to assess a patient's immunological response. The method involves measuring a frequency shift of the PEMS caused by binding the immunological response factors to one or more receptors on the PEMS. The method may be used to determine the effectiveness of a prescribed therapeutic treatment and/or monitor the progress of a disease. | 04-14-2011 |
20110097744 | Cellular COPD Diagnosis - Method for diagnosing the risk of a human subject to develop chronic obstructive pulmonary disease (COPD) comprising the steps of:—providing a sample from a human subject,—determining the amount of CD4+CD28null T-cells in said sample,—diagnosing the risk to develop COPD when the amount of CD4+CD28null T-cells is reduced compared to the amount of CD4+CD28null T-cells in healthy human subjects. | 04-28-2011 |
20110104720 | Detection of Analytes Present in Exosomes - The invention provides methods for detection in stored biological samples of PrPsc and other analytes that are present in exosomes. | 05-05-2011 |
20110111437 | Biomarkers For Prognosis of Pulmonary Diseases - The present invention relates to biomarkers that may be used to evaluate the prognoses of patients suffering from pulmonary diseases and assist in the determination of appropriate therapeutic regimens. It is based, at least in part, on the discovery that a number of T-cell antigens are differentially expressed in chronic lung disease patients depending on the prognosis of the patient. Non-limiting examples of these antigens include CD28, CD4, CD25, CD45, CD27 and CCR7 and combinations thereof. Use of these biomarker antigens, optionally in conjunction with pulmonary function tests, provides an indication of which patients are likely to suffer a severely adverse outcome within the year and/or be refractory to treatment. | 05-12-2011 |
20110117578 | BIOMARKER FOR SELECTING PATIENTS AND RELATED METHODS - The present invention concerns methods for inducing an immune response to an antigen in a patient for treating human disease by administering an immunogenic composition wherein said patient is selected in a patient population of interest. The present invention further concerns methods for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment. | 05-19-2011 |
20110117579 | System and Method for Quantitative Assessment of Biological Migration Behavior - The present invention provides systems and methods for assessing migration behavior of biological particles, such as neutrophils, under the effect of a gradient. The systems can include one or more migration chambers, one or more gradient sources configured to generate particular gradients, e.g., of chemokines or the like across the width of the migration chamber, and a detection arrangement that is configured to determine spatial profiles across the migration chamber that indicate the extent of migration. | 05-19-2011 |
20110124017 | KIT FOR DIAGNOSIS, PROGNOSIS, AND MONITORING THE IMMUNE STATUS, OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES - Provided is a method and a kit for testing the immune status of patients with chronic inflammatory diseases by measuring the TCR zeta chain (CD247) expression levels, and in particular a method and a kit for testing the selective downregulation of TCR zeta chain expression in T cells, NK cells, or NKT cells of such patients. Zeta chain expression is measured using antibodies directed against the intracellular zeta chain region, and these levels are compared with the expression levels of other T cell receptor subunits and NK cell markers. Thus, a kit for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases is presented herein. | 05-26-2011 |
20110129857 | Methods Of Detecting Or Monitoring Activity Of An Inflammatory Condition Or Neurodegenerative Condition - An isolated aggrefatin protein elevated in multiple sclerosis patients as compared to healthy controls. Aggrefatin alone or in combination with other markers may be used as an indicator of an inflammatory condition and/or a neurodegenerative disease or condition such as multiple sclerosis, cancer, stroke, or other diseases. Aggrefatin alone or in combination with one or more other biomarkers may help monitor disease activity, detect a response to a therapy, or detect patient compliance with a therapy. | 06-02-2011 |
20110136151 | ASSAYS FOR DIAGNOSING AND EVALUATING TREATMENT OPTIONS FOR POMPE DISEASE - Provided are in vitro, ex vivo and in vivo methods for determining whether a patient with Pompe disease will respond to treatment with a specific pharmacological chaperone. | 06-09-2011 |
20110165597 | METHOD FOR THE SCREENING OF CONSERVED SECRETED PROTEINS - Conserved polypeptides from protozoan parasitic species which are secreted through the endoplasmic reticulum/Golgi dependent secretory pathway, their identification and their use. | 07-07-2011 |
20110171664 | METHODS AND REAGENTS FOR DETECTING SUSCEPTIBILITY TO GRAFT VERSUS HOST DISEASE OR TRANSPLANT RELATED MORTALITY - The present invention provides methods for determining the likelihood and/or severity of GvHD and the likelihood of the occurrence of transplant related mortality. | 07-14-2011 |
20110171665 | P-SELECTIN ASSOCIATED WITH EOSINOPHILS AS A MARKER FOR ASTHMA AND CORRELATING WITH B-1 INTEGRIN ACTIVATION - Methods are provided for the detection of P-selectin associated with eosinophils and for the use of P-selectin as a biological marker for asthma. In one embodiment, the present invention relates to methods for detecting P-selectin in a sample containing eosinophils and quantifying the total number of eosinophils. In another embodiment, the present invention relates a method for determining the proportion of eosinophils that are P-selectin positive and positive for at least partially activated β-1 integrin. In yet another embodiment, the present invention relates to kits for the detection of P-selectin and for the detection of eosinophils that are both P-selectin positive and positive for at least partially activated β-1 integrin. In still yet another embodiment, the invention relates to a method for monitoring a biological condition. | 07-14-2011 |
20110177529 | RAPID NASAL ASSAY KIT - The present invention relates to an assay which can be used on nasal secretions. The assay is used to determine the cause of nasal secretions, for example whether the secretions are due to an allergic reaction or a non-allergic reaction. | 07-21-2011 |
20110195435 | USE OF A PROTEIN KINASE INHIBITOR TO DETECT IMMUNE CELLS, SUCH AS T CELLS - The invention relates to a method for sorting, staining or detecting T cells of the immune system using a protein kinase inhibitor. | 08-11-2011 |
20110195436 | METHODS FOR THE CLASSIFICATION AND DIAGNOSIS OF SCOLIOSIS THROUGH THE USE OF GI PROTEIN RECEPTOR - Methods for diagnosing a predisposition to developing a scoliosis (e.g., adolescent idiopathic scoliosis (AIS)) and identifying compounds for treating scoliosis based on the modulation of Gi protein-coupled receptor activity are described. Specific embodiments of the methods involve measuring a change in impedance signals of cells expressing a receptor coupled to a Gi protein with a ligand. To identify compounds useful in treatment, the cell is contacted with a test compound and a ligand. A higher impedance in the presence relative to the absence of said test compound is indicative that the test compound is useful for treating scoliosis. | 08-11-2011 |
20110201031 | PREPARATION METHOD - A method of performing an immunologic evaluation of a subject, comprising collecting a whole blood sample from the subject, maintaining the sample for at least 6 hours after collection, purifying a population of cells comprising lymphocytes and antigen presenting cells from the maintained sample, optionally by a process incorporating a positive or negative affinity selection step to remove granulocytes, and using the purified cells in a cell-mediated immunoassay (CMI assay). | 08-18-2011 |
20110207150 | CELL ASSAY KIT AND METHOD - A method and kit for assaying a cell sample for the presence of at least a threshold number of cells of a given type are disclosed. The kit includes an assay device having a sample chamber for receiving the cell sample and an elongate collection chamber containing a selected-density and/or viscosity medium and having along its length, a plurality of cell-collection regions, and particles which are capable of specific attachment to cells of the selected cell type, and which are effective, when attached to the cells, to increase the density or magnetic susceptibility of the cells. In operation, particle-bound cells and particles in the cell sample are drawn through the elongate collection chamber under the influence of a gravitational or selected centrifugal or magnetic-field force until the particle-bound cells and particles completely fill successive cell-collection regions in the collection chamber. Indicia associated with at least one collection regions indicates a concentration of cells of the selected type effective to at least partially fill that collection region. | 08-25-2011 |
20110250619 | Methods of Detecting Antibodies Specific for Denatured HLA Antigens - The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ. | 10-13-2011 |
20110250620 | METHODS OF EVALUATING AN IMMUNE RESPONSE TO AN ANTIGEN - The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days. | 10-13-2011 |
20110269154 | Methods for Diagnosis, Prognosis and Methods of Treatment - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 11-03-2011 |
20110269155 | Detecting Antigen Responsive Cells in a Sample - The present invention relates to methods for detecting antigen responsive cells in a sample using multidimensional labeled antigen presenting compounds, such as antigen-major histocompatibility complexes (NHC). Further, the present invention relates to the use of the present multidimensional labeled antigen presenting compounds, such as antigen-major histocompatibility complexes (MHC), for detecting antigen responsive cells in a sample, preferably a single sample, such as a blood sample. The present method allows high-throughput analysis of specific antigen responsive cells, such as T- and B-cells, thereby providing, for example, high-throughput methods for monitoring of diseases or conditions and the development of immunotherapeutics, vaccines, or the identification epitopes or immunogenic amino acid sequences. | 11-03-2011 |
20110311992 | Method of Prognosis and/or Diagnosing an IRS in a Patient Infected with M. Tuberculosis and Optionally HIV - The invention relates to a method of prognosing and/or diagnosing a | 12-22-2011 |
20120028276 | METHODS FOR DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES (MDS) - The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS. | 02-02-2012 |
20120028277 | PREPARATION METHOD - A method of performing an immunologic evaluation of a subject, comprising collecting a whole blood sample from the subject, maintaining the sample for at least 6 hours after collection, purifying a population of cells comprising lymphocytes and antigen presenting cells from the maintained sample, optionally by a process incorporating a positive or negative affinity selection step to remove granulocytes, and using the purified cells in a cell-mediated immunoassay (CMI assay). | 02-02-2012 |
20120058493 | BIOMARKER FOR MONITORING PATIENTS - The present invention is in the field of immunotherapy and relates to methods for determining the efficacy of certain immunotherapy treatments. The methods of the invention include measuring special biomarker at some time following the initiation of immunotherapy treatment to evaluate the clinical outcome of the said treatment. The invention thus has applications to the field of medicine. | 03-08-2012 |
20120083007 | Basophil Activation Based Allergy Diagnostic Test - Methods are provided for determining a subject's susceptibility to an allergic reaction upon exposure to an offending allergen. Methods are also provided for determining and monitoring a subject's responsiveness to ongoing allergy treatment. | 04-05-2012 |
20120094312 | BOOSTING HUMAN DENDRITIC CELL DEVELOPMENT, HOMEOSTASIS AND FUNCTION IN XENOGRAFTED IMMUNODEFICIENT MICE - The present invention relates to a transgenic animal mode system based on the development of transgenic mice bearing components of the human immune system. Specifically, the Invention relates to a Flk2 deficient Rag “γc” transgenic mouse and the engraftment of said mouse with human hematopoietic stem cells. The present invention further presides methods for increasing the numbers of functionally competent human dendritic cells is and the hematopoietic targets cells that they interact with in said transgenic mouse through the administration of Flk2L. The transgenic animal model system of the invention may be used for testing human vaccine candidates, for screening potential Immune adjuvants and for developing novel therapeutics. | 04-19-2012 |
20120107840 | Methods for Label Free Testing of Cells - The invention provides methods of detecting activation of an immune cell, methods for detecting blocking or enhancing properties of a test reagent or stimuli on activation of one or more immune cells or platelets, methods for selecting hybridomas producing antibodies to an antigen for quality of strength of binding to the antigen, methods for determining if a subject has had an immune response to an immunogen, methods of isolating neutralizing antibodies for an immunogen, methods of classifying a B cell lymphoma, and methods for selecting activated B-cells expressing an antibody to one or more antigens. | 05-03-2012 |
20120122122 | METHOD OF DIAGNOSING CANCER - A method of diagnosing cancer is provided. The method comprising determining a level of CEACAM1 on isolated peripheral blood lymphocytes (PBLs) of a subject in need thereof, wherein an upregulation of the level of CEACAM1 above a predetermined threshold is indicative of cancer in said subject. | 05-17-2012 |
20120129193 | DEVICE AND METHOD FOR ANALYSING CELLS - There is provided a carrier substrate for nonspecific immobilization of living bacterial and/or eukaryotic cells, especially of animal cells, which can be present as single cells, cell agglomerates or tissue sections. The surface of the carrier substrate is provided at least sectionally with a layer having or consisting of oligonucleic acids, preferably having ribonucleic acids covalently coupled to the carrier substrate, e.g. RNA, preferably single-stranded or double-stranded DNA. | 05-24-2012 |
20120142031 | REAL TIME ELECTRONIC CELL SENSING SYSTEMS AND APPLICATIONS FOR CELL-BASED ASSAYS - The present invention includes devices, systems, and methods for assaying cells using cell-substrate impedance monitoring. In one aspect, the invention provides cell-substrate impedance monitoring devices that comprise electrode arrays on a nonconducting substrate, in which each of the arrays has an approximately uniform electrode resistance across the entire array. In another aspect, the invention provides cellular assays that use impedance monitoring to detect changes in cell behavior or state. In some preferred aspects, the assays are designed to investigate the affects of compounds on cells, such as cytotoxicity assays. | 06-07-2012 |
20120142032 | MULTI-FREQUENCY IMPEDANCE METHOD AND APPARATUS FOR DISCRIMINATING AND COUNTING PARTICLES EXPRESSING A SPECIFIC MARKER - An analysis method for identifying and counting particles expressing a specific antigenic marker is proposed. One example (but not exclusive) is CD4+ T-lymphocyte analysis in blood. The method comprises obtaining a sample comprising particles in suspension, labeling the particles expressing the specific marker with an impedance label, and measuring the labeled sample using a dual frequency system to discriminate at least the labeled particles expressing the specific marker. The method allows an accurate count of particles e.g. the number CD4+ T-lymphocytes in a blood flow. A corresponding device is also provided. | 06-07-2012 |
20120156699 | Pathogenic TH17 Cells; related reagents and methods - Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders. | 06-21-2012 |
20120164665 | Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 06-28-2012 |
20120171701 | IDENTIFICATION OF REGULATORY T CELLS VIA THE GLOBAL GENE REGULATOR SATB1 - A method for the identification of regulatory T cells based on the diminished abundance or even absence of the global gene regulator SATB1 in such regulatory T cells. In particular, the invention relates to a method utilizing ligands that specifically bind to SATB1 for identifying regulatory T cells which are cells showing a reduced binding to said ligand. Such method is suitable for quality determination of a regulatory T cell population. A kit or diagnostic composition for such method is also disclosed. | 07-05-2012 |
20120183976 | METHODS OF ASSESSING ACTIVITY OF A POLYSACCHARIDE COMPOSITION - Methods of assessing polysaccharide preparations lacking substantial anticoagulant activity are provided herein. | 07-19-2012 |
20120196302 | DETECTING METHOD - A detecting method is herein disclosed. The method includes steps of providing an eukaryotic cell, having a cell nucleus and a cell membrane, wherein the cell nucleus endogenetically translates a first receptor and a second receptor, and wherein the first receptor and the second receptor pass through the cell nucleus and translocate to the cell membrane; coupling the first receptor to a first bioactive ligand with a quantum dot; washing the cell coupled with the first bioactive ligand and the quantum dot by centrifugation; coupling the second receptor to a second bioactive ligand with a magnetic bead; washing the cell coupled with the first bioactive ligand and the second bioactive ligand by magnetic separation; irradiating a exciting energy for the quantum dot to emit a fluorescence, wherein the quantum dot coupled with the cell is excited in a pH range from pH 9 to pH 14; and detecting the fluorescence. | 08-02-2012 |
20120202223 | Ki-67 ASSAY FOR PATIENT IMMUNE SYSTEM STATUS - Novel diagnostic assay based on the detection of Ki-67 expression to anticipate the response to anti-HIV therapy | 08-09-2012 |
20120202224 | POLYPEPTIDE VARIANTS WITH ALTERED EFFECTOR FUNCTION - The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof. | 08-09-2012 |
20120219970 | METHODS FOR MODULATING MACROPHAGE PROLIFERATION IN OCULAR DISEASE USING POLYAMINE ANALOGS - Methods for modulating macrophage proliferation in an individual afflicted with or at risk for an ocular disease such as ARMD are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including ARMD. The invention also provides methods for aiding diagnosis and monitoring therapy of an ocular disease such as ARMD. | 08-30-2012 |
20120237954 | BIOMARKERS FOR PROGNOSES OF PULMONARY DISEASES - The present invention relates to biomarkers that may be used to evaluate the prognoses of patients suffering from pulmonary diseases and assist in the determination of appropriate therapeutic regimens. It is based, at least in part, on the discovery that a number of T-cell antigens are differentially expressed in chronic lung disease patients depending on the prognosis of the patient. Non-limiting examples of these antigens include CD28, CD4, CD25, CD45, CD27 and CCR7 and combinations thereof. Use of these biomarker antigens, optionally in conjunction with pulmonary function tests, provides an indication of which patients are likely to suffer a severely adverse outcome within the year and/or be refractory to treatment. | 09-20-2012 |
20120258476 | METHODS FOR INDUCING A NATURAL KILLER (NK) CELL-MEDIATED IMMUNE RESPONSE AND FOR INCREASING NK CELL ACTIVITY - This disclosure relates to methods of inducing a natural killer (NK) cell-mediated immune response and increasing NK activity in a mammal for the treatment of tumors and virus infections, comprising isolating peripheral blood mononuclear cells (PBMCs) from a subject, exposing them in vitro to a protein conjugate comprising granulocyte macrophage colony stimulating factor (GM-CSF) covalently linked to a soluble peptide antigen to activate the PBMCs, and administering the activated PBMCs to the subject. The method also relates to assessing NK cell activity of activated PBMCs to determine whether the subject has had a therapeutically effective response to the protein conjugate. | 10-11-2012 |
20120264141 | TUBERCULOSIS DIAGNOSTIC TEST - A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided. | 10-18-2012 |
20120264142 | DETECTION OF B-CELL ACTIVATING FACTOR AS A BIOMARKER FOR ANTIBODY MEDIATED REJECTION IN TRANSPLANT RECIPIENTS - The invention relate to methods, compositions, and kits for detection of biomarkers. hi one embodiment, the invention relates to a method for detecting AMR biomarkers in a biological sample. In another embodiment, the invention relates to a method for detecting, monitoring, diagnosing and predicting antibody mediated rejection. In yet another embodiment, the invention relates to a method for monitoring a subject for antibody mediated rejection comprising detecting BAFF or a BAFF variant in a biological sample. In still another embodiment, the invention relates to a kit for detecting BAFF in a urine sample. | 10-18-2012 |
20120276556 | Ligating BDCA-2 Protein for the Purpose of Isolating or Modulating Dendritic Cells - The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby. | 11-01-2012 |
20120276557 | METHOD FOR THE QUANTITATIVE AND QUALITATIVE CHARACTERIZATION OF ANTIGEN-SPECIFIC T CELLS RECOGNIZING A SPECIFIC ANTIGEN - The invention relates to a method for sensitive quantitative and/or qualitative analysis of target T cells comprising the steps a) enrichment of said cells from a mixture of said cells and other cells in a sample by the use of one or more activation markers expressed on antigen-activated T cells in a parallel cell sorting process and b) analysis of the cells of step a). | 11-01-2012 |
20120276558 | KITS FOR MULTIPARAMETRIC PHOSPHO ANALYSIS - As disclosed herein, the present invention provides for kits and a composition for diagnosis, prognosis, drug discovery, drug development, and patient stratification. The kits can comprise a plurality of binding elements for cell surface markers, and a plurality of binding elements for state-specific intracellular markers. The kits can further comprise a plurality of modulators directed for the particular cell function or signaling pathways. The kits can further include fixatives, permeabilizing agent, buffers, containers, instructions, and software for data analysis/compilation. | 11-01-2012 |
20120288878 | METHODS FOR IDENTIFYING IMMUNOBINDERS OF CELL-SURFACE ANTIGENS - The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods. | 11-15-2012 |
20120309030 | METHOD FOR DETERMINING RISK OF DIABETES - A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbAIc; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I. | 12-06-2012 |
20120309031 | ANTIBODIES THAT BIND HUMAN DENDRITIC AND EPITHELIAL CELL 205 (DEC-205) - Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antib | 12-06-2012 |
20120315653 | SEPSIS TEST - There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection. | 12-13-2012 |
20120322085 | THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES OR ALLERGY, AND METHOD FOR SCREENING FOR THE THERAPEUTIC AGENT - Disclosed is a therapeutic agent for treating a cellular immune disease, comprising as an active ingredient a substance that inhibits binding between Sema3A and a Neuropilin-1/Plexin-A1 heteroreceptor. The substance includes, for example, a Sema3A neutralizing antibody, a Neuropilin-1 neutralizing antibody, or a soluble Neuropilin-1 or derivative thereof. Also disclosed is a method for screening a therapeutic agent for treating a cellular immune disease utilizing a signal generated by the interactions of Neuropilin-1, Plexin-A1 and Sema3A as a marker. | 12-20-2012 |
20130017560 | VIRAL CITRULLINATED PEPTIDES AND USES THEREOFAANM Migliorini; PaolaAACI SienaAACO ITAAGP Migliorini; Paola Siena ITAANM Pratesi; FedericoAACI SienaAACO ITAAGP Pratesi; Federico Siena IT - The present invention relates to an antigenically effective peptide comprising, from the amino to the carboxylic terminal, the amino acid sequence: G P P W W P P I C D P P Q P S K T Q G Q S X | 01-17-2013 |
20130022996 | GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., | 01-24-2013 |
20130029358 | IMMUNODOMINANT MHC DR52B RESTRICTED NY-ESO-1 EPITOPES, MHC CLASS II MONOMERS AND MULTIMERS, AND USES THEREOF - Immunostimulatory NY-ESO-1 epitopes recognized by MHC-DRB3*0202 (DR52b) or DRB1*0101 (DR1) restricted T cells are described. Methods for their use in diagnostic and therapeutic approaches are also provided. Further, methods for the generation and isolation of MHC class II molecules, either “empty” or peptide-loaded, are provided. Methods for the assembly of MHC class II multimers, for example, tetramers, are also provided. Methods for the detection of T cells binding to specific peptide-loaded MHC class II molecules are also described herein. | 01-31-2013 |
20130045491 | METHODS FOR ACTIVATING T CELLS - The present invention is directed to a method for promoting function, activation and proliferation of T helper lymphocytes such as those that express IL17 and IL22 (Th-IL17+ and Th-IL22+ T cells). The method features isolating a population of T cells from a subject such as a human and incubating the population of T cells in a serum-free culture medium that contains one or more cytokine. The T cells may be memory T cells (T | 02-21-2013 |
20130071860 | METHODS FOR AUTOIMMUNE DISEASE DIAGNOSIS, PROGNOSIS, AND TREATMENT` - In one aspect, the present invention provides methods for the classification, diagnosis, prognosis, theranosis, and/or prediction of an outcome of an autoimmune disease in a subject. | 03-21-2013 |
20130109032 | USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS | 05-02-2013 |
20130115630 | AUTOMATED MULTIPLEX IMMUNOASSAY - Embodiments relate generally to an automated multiplex immunoassay for qualitatively and/or quantitatively detecting a plurality of targets on a tissue sample. Kits and apparatuses for practicing such assays are also provided. | 05-09-2013 |
20130122523 | IN VITRO PROCESS FOR THE QUICK DETERMAINATION OF A PATIENT'S STATUS RELATING TO INFECTION WITH MYCOBACTERIUM TUBERCULOSIS - An in-vitro process for the quick determination of the infection status of a | 05-16-2013 |
20130122524 | Methods for Diagnosis, Prognosis and Methods of Treatment - This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of a cell present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. | 05-16-2013 |
20130149719 | Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents - The present invention is directed to proteins expressed by | 06-13-2013 |
20130171668 | DISULPHIDE BOND-STABILIZED FUNCTIONAL SOLUBLE MHC CLASS II HETERODIMERS - The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II α chain; (ii) all or part of the extracellular portion of an MHC class II β chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the α2 domain of said α chain and the β2 domain of said β chain, wherein said cysteine residues are not present in native MHC class II α2 and β2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects. | 07-04-2013 |
20130183686 | METHOD OF EVALUATING IMMUNOSUPPRESSION - Provided is a method for determining immunosuppression in an individual. The method entails testing blood cells for nuclear NFkB and/or nuclear NFAT. The blood cells can be from a sample of blood from an individual. The cells can be contacted with an activating agent to obtain activated cells, and the amount of nuclear NFkB and/or NFAT can be compared to a control. An amount of nuclear NFkB and/or NFAT that is higher than the control is considered to be indicative of insufficient immunosuppression in the individual. An amount of nuclear NFkB and/or NFAT that is lower than the control is considered to be indicative of excessive immunosuppression in the individual. An amount of nuclear NFkB and/or NFAT that is the same as the control is considered to be indicative of an appropriate amount of immunosuppression in the individual. | 07-18-2013 |
20130217038 | MULTIPARAMETRIC METHOD FOR ASSESSING IMMUNE SYSTEM STATUS - The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event. | 08-22-2013 |
20130230867 | Software Integrated Flow Cytometric Assay For Quantification Of The Human Polymorphonuclear Leukocyte FCgammaRI Receptor (CD64) - A composition for evaluating a biological condition is disclosed. The composition has (a) a sample composition comprising at least one of: i.) a bodily specimen comprising a target moiety; ii.) a positive control moiety; and iii.) a negative control moiety; (b) an antibody composition comprising at least one of: i.) at least one target antibody; ii.) at least one positive control identifying antibody; and iii.) at least one negative control identifying antibody; and (c) at least one reference composition comprising at least one of: i.) a target signal reference composition; and ii.) a reference identifier composition. | 09-05-2013 |
20130236914 | DEVICES AND METHODS FOR ANALYSIS OF SAMPLES WITH DEPLETION OF ANALYTE CONTENT - A system and method for determining the presence and/or concentration of one or more analytes in a sample that comprises a fluid, the system comprising a solid substrate comprising a sample inlet or inlets and one or more analyte determination flow paths, each analyte determination flow path comprising a defined beginning and a defined terminus and comprising at least one capture zone containing a capture agent for an analyte, the capture agent or agents being immobilized along a portion of the flow path or paths, the flow path or paths being designed so that the one or more analytes are depleted from the sample and bound in a non-linear manner to the portion of the flow path or paths containing immobilized capture agent or agents, producing an analyte depletion end region for each analyte between the beginning and the terminus of the analyte determination flow path. | 09-12-2013 |
20130252260 | USE OF AMINO ACID SEQUENCES FROM MYCOBACTERIUM TUBERCULOSIS OR CORRESPONDING NUCLEIC ACIDS FOR DIAGNOSIS AND PREVENTION OF TUBERCULAR INFECTION, DIAGNOSTIC KIT AND VACCINE THEREFROM - The present invention refers to the use of gene sequences or portions thereof characterized in that the same belong to the classes of in vitro and ex vivo induced, repressed or conserved genes in | 09-26-2013 |
20130260394 | METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF INFLAMMATORY STATES - The invention relates to a method for the diagnosis and/or prognosis of inflammatory states. | 10-03-2013 |
20130260395 | METHOD FOR THE DIAGNOSIS OF AND/OR MONITORING MUCORMYCOSIS - A method is described for the diagnosis and/or monitoring of active or previous infection by Mucor which consists in the identification of Mucorales-specific T cells in samples from biological fluids taken from the patient and put into contact with a Mucor antigen. These specific immune responses can be detected by the execution of immunoenzymatic assays (ELISPOT, Quantiferon) or of immunocytofluorimetric assays [Cytokine Secretion Assay (CSA), Intracellular Cytokine Staining (ICS)] in vitro. In greater detail, the method in question provides for checking for the presence of specific IFN-γ producing T cells, of specific IL-10 producing T cells and/or specific IL-4 producing T cells. | 10-03-2013 |
20130266966 | METHOD OF DETERMINING RISK OF SCOLIOSIS - A method for determining the risk for developing a scoliosis comprising monitoring osteopontin (OPN) expression in a sample from a subject over time; wherein an OPN expression that increases in the subject sample over time is indicative that the subject is at risk for developing a scoliosis. | 10-10-2013 |
20130266967 | FUNCTION HOMOLOGY SCREENING - A method of screening biologically active agent based on the analysis of complex biological responses in culture. Methods for selecting cells and culture conditions for such screens are provided, as well as the identification of an optimized set of discrete parameters to be measured, and the use of biomap analysis for rapid identification and characterization of drug candidates, genetic sequences acting pathways, and the like. A feature of the invention is simultaneous screening of a large number of cellular pathways, and the rapid identification of compounds that cause cellular responses. | 10-10-2013 |
20130295588 | COUNTING PARTICLES USING AN ELECTRICAL DIFFERENTIAL COUNTER - This disclosure relates to methods and devices to count particles of interest, such as cells. The methods include obtaining a fluid sample that may contain particles of interest; counting all types of particles in a portion of the sample using a first electrical differential counter to generate a first total; removing any particles of interest from the portion of the fluid sample; counting any particles remaining in the portion of the fluid sample using a second electrical differential counter after the particles of interest are removed to generate a second total; and calculating a number of particles of interest originally in the fluid sample by subtracting the second total from the first total, wherein the difference is the number of particles of interest in the sample. These methods and related devices can be used, for example, to produce a robust, inexpensive diagnostic kit for CD4+ T cell counting in whole blood samples. | 11-07-2013 |
20130309692 | MARKERS FOR DETECTING HUMAN FOLLICULAR HELPER T CELLS AND METHOD FOR DETECTING HUMAN FOLLICULAR HELPER T CELLS - The present invention relates to polynucleotide markers and protein markers for detecting human follicular helper T cells. The present invention also relates to methods for detecting human follicular helper T cells using the markers. | 11-21-2013 |
20130316375 | DIABETES BIOMARKERS - A new markers for insulin production decline in Type 1 diabetes has been found in the ratio the CD4 naïve (CD45RO-CD62L+) to central memory (CD45RO+CD62L+) and in the level of CD4 central memory T-cell subpopulations. A method of diagnosing autoimmunity and its progressiveness, more specifically diabetes, pre-diabetes, a susceptibility to diabetes mellitus, or the level of effectiveness of therapy/intervention modality for one or more of such conditions in a subject can be conducted by determining level of CD4 naïve (CD45RO-CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject; determining level of CD4 central memory (CD45RO+CD62L+) T-cells by immunofluorescence analysis of a sample extracted from a subject, and quantitatively relating the levels of the CD4 naïve and central memory T-cells, wherein a low ratio of CD4 naïve T-cells to CD4 central memory T-cells and/or high CD4 central memory T-cell indicates autoimmunity, a susceptibility to autoimmunity, diabetes, pre-diabetes, a susceptibility to diabetes mellitus or ineffectiveness of a treatment for one or more of such conditions. | 11-28-2013 |
20130316376 | SPIDER SILK FUSION PROTEIN STRUCTURES FOR BINDING TO AN ORGANIC TARGET - A protein structure capable of selective interaction with an organic target is provided. The protein structure is a polymer comprising as a repeating structural unit a recombinant fusion protein that is capable of selective interaction with the organic target. The fusion protein is comprising the moieties B, REP and CT, and optionally NT. B is a non-spidroin moiety of more than 30 amino acid residues, which provides the capacity of selective interaction with the organic target. REP is a moiety of from 70 to 300 amino acid residues and is derived from the repetitive fragment of a spider silk protein. CT is a moiety of from 70 to 120 amino acid residues and is derived from the C-terminal fragment of a spider silk protein. NT is an optional moiety of from 100 to 160 amino acid residues and is derived from the N-terminal fragment of a spider silk protein. The fusion protein and protein structure thereof is useful as an affinity medium and a cell scaffold material. | 11-28-2013 |
20130344511 | USE OF HEMATOPOIETIC GROWTH FACTOR INDUCIBLE NEUROKININ-1 (HGFIN) AS A NOVEL BIOMARKER - The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for hematopoietic growth factor inducible neurokinin-1 (HGFIN), wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of renal injury or renal disease, and/or the rate of loss of renal function. In other embodiments, the invention provides a method of detecting an indicator of systemic inflammation. This method entails assaying a biological sample for HGFIN, wherein the presence of HGFIN at an elevated level indicates the presence and/or degree of systemic inflammation. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment. | 12-26-2013 |
20130344512 | CD16A REPORTER ASSAY FOR EVALUATION OF ADCC POTENTIAL OF BIOLOGICS - The present invention provides a method for determining whether an antibody or antigen-binding fragment thereof will cause ADCC when administered to a subject. Host cells that may be used in such a method are also provided. | 12-26-2013 |
20140004537 | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF | 01-02-2014 |
20140030737 | IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES - Methods, devices, systems, and apparatuses are provided for the image analysis of measurement of biological samples. | 01-30-2014 |
20140065644 | METHOD OF THERAPY - Numerous diseases have been linked to the production of regulator cells. The present invention relates to the observation that the immune system is cycling in these diseases. Based on these observations, the present invention provides methods for treating diseases such as cancer and a HIV infection. The present invention also relates to methods of determining when a therapy to treat a disease characterized by the production of regulator cells should be administered to a patient. | 03-06-2014 |
20140080147 | NOVEL CD3 EPSILON IMMUNOGENS AND ANTIBODIES - The present invention relates to novel CD3 epsilon peptides, antibodies against the novel CD3 epsilon peptides. The invention also relates to methods of identifying an immunodeficiency (such as severe combined immunodeficiency (SCID) or a T cell immunodeficiency) in a patient, which may involve antibodies against CD3 epsilon peptides. | 03-20-2014 |
20140080148 | Generation of NK Cells and NK-Cell Progenitors - The present invention provides a cytokine-based culture method for ex vivo expansion of NK cells from postembryonic hematopoietic stem cells into a fully closed, large-scale, cell culture bioprocess. We optimized enrichment of CD34 | 03-20-2014 |
20140080149 | Method and Arrangement for Quantifying Subgroups from a Mixed Population of Cells - A method for determining the mass and concentration of certain particles or cells from a mixed population of cells, such as a patient's blood sample. The cells to be determined are each marked with a monoclonal antibody, to which colloidal iron is coupled. The blood sample is filled into a test tube with a capillary section and a magnet is used to gather the marked cells and move them to the capillary section. A test tube rack is constructed to hold the test tube with the capillary section and a measurement scale is provided for determining the mass and concentration of the marked cells. | 03-20-2014 |
20140080150 | METHOD AND KIT FOR RAPID ISOLATION OF HUMAN FOXP3+ TREG CELLS - The present invention relates to methods for isolating human forkhead box P3 (Foxp3+) CD4+ regulatory T cells (herein referred to a Foxp3+ Treg cells) from a sample containing (i) peripheral blood mononuclear cells (PBMCs), (ii) a lymphocyte containing fluid, or (iii) a lymphocyte containing tissue, a kit for isolating human Foxp3+ Treg cells, and the use of anti-CD49d antibody for the isolation of human Foxp3+ Treg cells. | 03-20-2014 |
20140087394 | Instrument Setup System for a Fluorescence Analyzer - The present invention reagents and methods for setting up an instruments having a multiplicity of detector channels for analyzing a multiplicity of fluorescent dyes. The present invention is particularly applicable in the field of flow cytometry. | 03-27-2014 |
20140113315 | Cell separation method using a release system for cell-antibody-substrate conjugates containing a polyethylene glycol spacer unit - The invention is directed to a releasable conjugate comprising a biotinylated ligand having a biotin moiety, a ligand moiety (Ligand | 04-24-2014 |
20140113316 | DEVICE, METHOD AND KIT FOR THE DETECTION OF DIFFERENT MARKERS IN DIFFERENT CELLULAR OR MOLECULAR TYPES AND THEIR QUANTIFICATIONS - Microplates or microstrips having wells with extended length to receive immunosorbent elements protruding from a rod at the same modular distance of wells arranged in standard microstrips or microplates and methods of use are provided. A solid phase is constituted by the extended wells, each of which immobilize a different type of cell or molecule in the sample; the other solid phase is constituted by immunosorbent elements protruding from a rod, each of which has been previously coated with one of the same markers to be detected in the sample. Ligands for markers to be detected are added in a liquid phase to the wells; allowing the ligands competitively bind to the immunosorbent elements, inversely proportional to the quantity of the markers of each type of cell or molecule immobilized on the proper extended well. These ligands are simultaneously quantifiable by an immunoenzymatic assay using chromogenic substrate and a spectrophotometer. | 04-24-2014 |
20140120556 | Particle Identification System, Cartridge And Associated Methods - A particle identification system includes: a cartridge for containing a sample with fluorescently labeled particles; illumination for illuminating a region within the cartridge to stimulate emission from particles; imager for generating wavelength-filtered electronic images of the emission within at least one measurement field of the region; and particle identifier for processing the electronic images to determine a superset of particles of interest, and fluorescently labeled particles within the superset based on properties of the particles in the at least one measurement field. A method determines fluorescently labeled particles within a sample, by: processing at least one electronic image from at least one focal position within the sample; determining dimmest separation lines between brighter areas in the electronic image; and, for each of the brighter areas, determining local background level based on pixel values of the separation lines forming a perimeter therearound, to determine each of the fluorescently labeled particles. | 05-01-2014 |
20140120557 | Photocrosslinkable Peptide-MHC Complexes for Antigen-Specific T Cells and Methods of Using the Same - Methods for labeling and/or detecting a T cell according to specificity of an antigen T cell receptor (TCR) are provided. Also provided are monomeric MHC-peptide complexes and kits for crosslinking to a T cell according to specificity of an antigen T cell receptor (TCR). The methods, monomeric MHC-peptide complexes and kits find use in a variety of applications related to the detection and purification of antigen-specific T cells, such as those T cells involved in tumors, infectious diseases and autoimmune diseases. | 05-01-2014 |
20140120558 | Detecting Cells Secreting A Protein Of Interest - In some cases, the described systems and methods include obtaining a cell sample containing multiple antibody-producing cells. In such cases, the cells can be tagged with a cross-linking reagent having a first portion configured to bind to a marker on the antibody-producing cells and a second portion configured to bind to an antigen of interest. In some instances, the tagged antibody-producing cells are exposed to the antigen of interest such that the antigen becomes bound to the cells. In some such instances, the antibody-producing cells are also allowed to produce an antibody, such that a portion of the antibody-producing cells produce an antigen-specific antibody that binds to the antigen of interest. To identify cells that produce the antigen-specific antibody, the tagged cells can be exposed to a labeled secondary antibody that is configured to bind to the antigen-specific antibody. Other implementations are also described. | 05-01-2014 |
20140127717 | HYDROXAMATE SUBSTITUTED AZAINDOLINE-CYANINE DYES AND BIOCONJUGATES OF THE SAME - Hydroxamate substituted azaindoline cyanine dyes, conjugates thereof and methods of using the same are provided. The subject cyanine dyes include an azaindoline ring having a hydroxamate substituent. The dyes may further include a reactive group moieties (RGM) and/or a water soluble group. Also provided are conjugates of the subject dyes. Also provided are tandem conjugates including a fluorescent protein capable of energy transfer to the dye. Methods of detecting an analyte in a sample by contacting the sample with a detection reagent are provided. The detection agent may be a dye-conjugate that specifically binds the analyte, or may be a reactive dye which conjugates to the analyte. Also provided are compositions, e.g., kits, etc., incorporating such dyes which facilitate use in such methods. | 05-08-2014 |
20140134647 | NOVEL CRYSTAL STRUCTURE AND LIGAND BINDING SITES OF TRAIL RECEPTOR - A composition comprising a TRAIL-R2 receptor or fragment thereof bound to a ligand in crystalline form is presently provided along with novel binding sites and binding agents of a TRAIL receptor. Also provided are methods of designing a compound, protein or peptide and identifying a binding agent that interacts with a TRAIL receptor. The present invention further provides methods of modulating binding of a TRAIL receptor to a ligand, the methods comprising contacting the TRAIL receptor with a binding agent, ligand, or an agonist or antagonist thereof, that interacts with a novel binding site described herein. | 05-15-2014 |
20140141455 | METHODS OF ASSAYING VACCINE POTENCY - Methods of assaying potency of a vaccine composition are provided. Said methods utilize a T cell receptor mimic that is reactive against a specific peptide/MHC complex. The potency of the vaccine is determined based upon the measured density of specific peptide/MHC complex present on the surface of the vaccine-treated antigen presenting cell. | 05-22-2014 |
20140162293 | GENE CODED FOR A MHC CLASS I MOLECULE, PLASMID, EXPRESSION SYSTEM PROTEIN, MULTIMER, REAGENT AND KIT TO ANALYZE A T CELL FREQUENCY - A gene coded for a MHC class I molecule. The MHC class I molecule comprises an ALPHA-1 helix and an ALPHA-2 helix. The gene is coded so that a bond is formed between the ALPHA-1 helix and the ALPHA-2 helix in the MHC class I molecule. | 06-12-2014 |
20140170678 | KITS, COMPOSITIONS AND METHODS FOR DETECTING A BIOLOGICAL CONDITION - The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject. | 06-19-2014 |
20140170679 | METHOD AND SYSTEM FOR CELL DETECTION AND ANALYSIS - The present invention is a method and a system of cell detection and analysis. The present invention may incorporate at least an optical source, a fluidic chip and a detection module. Cells may be caused to flow within the fluidic chip and specifically past a detection window section accessible by the optical source. The flowing cells may be identified and/or analyzed. The detection module may specifically count the cells of interest as they flow past the detection window section of the chip. The detection module may further be operable to generate or otherwise capture images of the cells as they flow past the window and to use these images collectively for the purpose of analyzing the cells. The present invention may be portable and operable in remote locations. | 06-19-2014 |
20140170680 | SYSTEMS, COMPOSITIONS AND METHODS FOR DETECTING A BIOLOGICAL CONDITION - Determining a biological condition in a mammal by using a cartridge, having fluidic open channels, sealable after receiving a fluid specimen, passing any of the specimen through any of the channels, contacting any reagent stored in a chamber with the specimen in a reaction chamber inducing a reaction and forming a reaction product, a mechanical controller including first urging means applying a force externally onto the chamber to release the reagent, second urging means applying a removable force onto the channels thereby inducing fluidic movement in a first direction in the channels and upon removal of the force causing fluidic movement in an opposite direction, alignment means aligning a reading channel on the cartridge for a detection to take place, an optical reader detecting the reaction product in the reading channel, and a processor receiving data from the optical reader and processing the data to determine the biological condition. | 06-19-2014 |
20140170681 | NOVEL ANTI-CXCR4 ANTIBODY AND ITS USE FOR THE DETECTION AND DIAGNOSIS OF CANCER - The present invention provides a novel, isolated anti-CXCR4 antibody for use in the diagnosis of cancer. In particular, the antibody of the invention recognizes monomeric and homodimeric CXCR4, but not heterodimeric CXCR4 | 06-19-2014 |
20140186858 | COMPOSITION FOR HIGH STRINGENCY CELL TREATMENT AND ANTIGEN RETRIEVAL - The present invention relates to a cell treatment composition for the permeabilization of fixed blood cells, to the use of said composition, to a method for the treatment of a biological sample comprising fixation of said sample and subsequently contacting said biological sample with said cell treatment composition. The invention further relates and to a kit comprising said cell treatment composition. | 07-03-2014 |
20140220599 | DIAGNOSIS METHOD OF ACTIVE TUBERCULOSIS - The present invention relates to a method for the in vitro diagnosis of active tuberculosis, comprising a step of contacting lymphocytes of a patient suspected to have active tuberculosis with at least one protein of mycobacteria, said protein being an enzyme having a lipolytic activity, and a step of detecting the presence of specific activated lymphocytes. | 08-07-2014 |
20140220600 | PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS DIAGNOSTIC REAGENTS AND VACCINES - The present invention is directed to reagents useful for generating immune responses to | 08-07-2014 |
20140273018 | FLOW-THROUGH CELL COUNTING ASSAY - A method for quantitatively measuring white blood cell (leukocyte) count and/or white blood cell (leukocyte) subsets count involves adding specific antibodies labeled with a marker to the biological fluid sample, capture of white blood cells from a fluid sample by a retainer, removal of other than leukocyte cells and other interfering substances by washing or using specific magnetic beads, and reading the result. The device for use in the present method includes a retainer for leukocyte cells and an absorption pad for taking up all excess washing solution flowing past the sample. | 09-18-2014 |
20140273019 | Methods of Evaluating BAFF - The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject. | 09-18-2014 |
20140287437 | MAGNETIC SEPARATION OF CELLS - An apparatus, system, and method for magnetic separation of cells are disclosed. By combining inkjet printing technology and magnetic labeling of cells, accurate cell counts are obtained using an optical microscope. Mouse CD4+ lymphocytes are attached to micron sized magnetic beads and printed through a modified, commercial inkjet printer. The labeled cells are then attached to a glass slide covering a permanent magnet. Cell counts can be obtained by use of regular and inverted optical microscopes and imaging software. The magnetically-labeled beads are collected for evaluation on a modified polymer coupon that is placed in front of a permanent magnet and the unlabeled cells fall into an excess container. Flow cytometry results verify the presence of the CD4+ protein on the LBRM-33 lymphocytes membrane. Protein-specific attachment of magnetic microspheres to the lymphocytes is utilized for sorting CD4+ lymphocytes. | 09-25-2014 |
20140287438 | Rapid and Inexpensive Assay for Evaluation of Antibody Efficacy with Custom-Designed Fluorescent Nanoparticles - A method for determining the efficacy of a vaccine comprising: providing serum from an animal inoculated with a vaccine; providing a plurality of antigen-linked nanoparticles; contacting the serum with the plurality of antigen linked nanoparticles; contacting the serum and the plurality of antigen linked nanoparticles with a plurality of Fc receptor-expressing cells; measuring amount antigen-linked nanoparticle uptake by of the Fc receptor-expressing cells; determining efficacy of the vaccine by comparing the level of antigen-linked nanoparticle uptake to a baseline level of uptake wherein a greater nanoparticle uptake compared to the baseline level of uptake is indicative of greater vaccine efficacy. | 09-25-2014 |
20140302530 | CMV GLYCOPROTEINS AND RECOMBINANT VECTORS - This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products. | 10-09-2014 |
20140335542 | MOLECULAR CHARACTERIZATION OF CIRCULATING TUMOR CELLS - The disclosed invention includes methods and kits for the removal of white blood cells from samples of enriched rare cells. | 11-13-2014 |
20140342375 | MICROFLUIDIC PROCESSING OF LEUKOCYTES FOR MOLECULAR DIAGNOSTIC TESTING - Described herein are microfluidic devices and methods that can greatly improve cell quality, streamline workflows, and lower costs. Applications include research and clinical diagnostics in cancer, infectious disease, and inflammatory disease, among other disease areas. | 11-20-2014 |
20140349312 | IN VITRO MODELLING OF HAEMATOPOIETIC STEM CELL MEDULLARY NESTS: A TOOL FOR STUDYING THE REGULATION OF HAEMATOPOIESIS, EVALUATING THE NESTING POTENTIAL OF A HAEMATOPOIETIC GRAFT AND TESTING THE PHARMACOTOXICOLOGY OF MEDICAMENTS - The present invention relates to a culture support for cultivating hematopoietic stem cells (HSCs) and/or hematopoietic progenitors (HPs), comprising a calcium biomaterial, osteoclasts, endothelial cells and mesenchymatous stem cells (MSCs) and/or osteoblasts and/or adipocytes. The present invention also relates to a method for preparing such a culture support, and an in vitro HSC and/or HP cultivation method. The use of such a culture support for studying cellular mechanisms involved in hematopoiesis and/or differentiation of HSC/HPs and/or for studying the efficacy and/or the toxicity of a medicament candidate is also described. | 11-27-2014 |
20140349313 | DATA ANALYSIS METHODS UTILIZING PHENOTYPIC PROPERTIES - The present invention provides a method of identifying sub-populations of cells in a cellular sample. Aspects of the method include categorizing cells of the cellular sample into at least a first and second population based on a first phenotypic property. The method may further include sub-categorizing each of the first and second population into sub-populations of cells based on a second and third phenotypic property, e.g., by using X detectable labels providing Y distinct signals, wherein X>Y, to identify sub-populations of cells in the cellular sample. | 11-27-2014 |
20140349314 | METHODS AND COMPOSITIONS FOR DETECTING AND TREATING INFLAMMATORY DISEASE - The invention features methods of diagnosing inflammatory disease based on the elevated presence microparticles (MP) expressing certain receptors. The invention also features methods of decreasing fibrosis in the liver by administering MP to subjects with liver fibrosis. | 11-27-2014 |
20140349315 | DISULPHIDE BOND-STABILIZED FUNCTIONAL SOLUBLE MHC CLASS II HETERODIMERS - The present invention relates to disulphide bond stabilized recombinant MHC class II molecules. In particular, the present invention provides a recombinant MHC class II molecule, which comprises: (i) all or part of the extracellular portion of an MHC class II α chain; (ii) all or part of the extracellular portion of an MHC class II β chain; wherein (i) and (ii) provide a functional peptide binding domain and wherein (i) and (ii) are linked by a disulphide bond between cysteine residues located in the α2 domain of said α chain and the β2 domain of said β chain, wherein said cysteine residues are not present in native MHC class II α2 and β2 domains. Methods of producing these molecules in prokaryotic systems and various uses of these molecules form further aspects. | 11-27-2014 |
20140370524 | METHOD FOR PRODUCING AN EXAMINATION REAGENT AND KIT FOR ANALYSING A T-CELL FREQUENCY - A method for producing an examination reagent includes adding a helper ligand to an unfolded receptor protein in an initial solution so as to provide a pre-solution of the examination reagent with a folded receptor protein. The folded receptor protein comprises a bonded helper ligand which can be exchanged with an examination peptide. | 12-18-2014 |
20150010923 | METHOD FOR LABELING INTRACELLULAR AND EXTRACELLULAR TARGETS OF LEUKOCYTES - The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods. | 01-08-2015 |
20150010924 | CD8+T-CELL SUBSETS AS MARKERS FOR PREDICTION OF DELAYED FRACTURE HEALING - The present invention relates to a method for diagnosis of delayed bone fracture healing, comprising determining the frequency of a subpopulation of CD8+ cells selected from a first group comprised of CD8+CD57+, CD8+CD28− and CD8+CD28−/CD57+, in a sample obtained from a subject. The present invention further relates to a system and a kit of parts for prediction and resulting options for preventing of delayed bone fracture healing. | 01-08-2015 |
20150024410 | METHOD FOR DETERMINING THE GLYCOSYLATION OF AN ANTIBODY - The invention relates to a method for detecting the binding of an antibody to an Fc receptor present on the surface of a cell as well as to a method for determining the level of glycosylation of an antibody. The invention also relates to a reagent kit for carrying out these methods. | 01-22-2015 |
20150024411 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS - The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials. | 01-22-2015 |
20150024412 | Humanized FcgammaR Mice - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided. | 01-22-2015 |
20150031051 | IMAGE ANALYSIS AND MEASUREMENT OF BIOLOGICAL SAMPLES - Methods, devices, apparatus, and systems are provided for image analysis. Methods of image analysis may include observation, measurement, and analysis of images of biological and other samples; devices, apparatus, and systems provided herein are useful for observation, measurement, and analysis of images of such samples. The methods, devices, apparatus, and systems disclosed herein provide advantages over other methods, devices, apparatus, and systems. | 01-29-2015 |
20150037819 | ANTI-HLA MONOCLONAL CHIMERIC IMMUNOGLOBULIN, METHOD AND KIT IMPLEMENTING SUCH A MONOCLONAL CHIMERIC IMMUNOGLOBULIN - A method for determining the quantity of anti-HLA antibodies of a liquid medium containing antibodies. | 02-05-2015 |
20150044696 | MICROFLUIDIC DEVICE FOR SERIAL FLUIDIC OPERATIONS - An integrated microfluidic device for carrying out a series of fluidic operations includes a housing including a plurality of n microfluidic conduits, wherein n is at least three, and a rotating valve having an internal channel with an entrance port and an exit port that are angularly separated. The rotating valve is positionable in a first position to connect two of the n fluidic conduits via the internal channel, and upon rotating the valve to a second position, two other of the n fluidic conduits are connected by the internal channel. The device further may include one or more fluidic chambers in fluid communication with respective fluidic conduits. Fluid contained in one fluidic chamber is transferrable by application of positive or negative gas pressure through associated fluidic conduits into another fluidic chamber via the internal channel. The device may be utilized to perform a variety of fluidic operations. | 02-12-2015 |
20150050670 | COMBINATORIAL GAMMA 9 DELTA 2 T CELL RECEPTOR CHAIN EXCHANGE - The current invention provides methods to identify γ9δ2T-cell receptors (γ9δ2TCR) that mediate anti-tumour responses. Surprisingly, it was now found that the CDR3 regions of the γ9-T-cell receptor chain and the δ2-T-Cell receptor chain (δ2TCR chain) are of importance. Based on these findings, combinatorial-γδTCR-chain-exchange (CTE) is proposed as an efficient method for identifying γ9δ2TCRs that mediate anti-tumour responses. Using the method of the invention, specific sequences of the respective γ9TCR and δ2TCR chains were identified that mediate anti-tumour responses. Hence, the invention further provides for specific γ9δ2TCRs, or fragments thereof, that may be used e.g. in diagnostics or treatment of cancer. The invention further provides for nucleic acid sequences, genetic constructs and retroviral vectors that can be used to express the γ9δ2TCRs according to the invention. | 02-19-2015 |
20150056636 | Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha - The present invention provides a transgenic mouse which comprises a deficiency for murine T lymphocytes, B lymphocytes and NK cells, a deficiency for murine MHC class I and MHC class II molecules, and a functional xenogenic SIRPα transgene. This mouse is useful for in vivo screening of various compounds, including immuno-therapeutic agents and vaccines. The said mouse is also useful for testing the in vivo metabolism of xenobiotic compounds. | 02-26-2015 |
20150064724 | BIOMARKERS FOR PROGNOSES OF PULMONARY DISEASES - The present invention relates to biomarkers that may be used to evaluate the prognoses of patients suffering from pulmonary diseases and assist in the determination of appropriate therapeutic regimens. It is based, at least in part, on the discovery that a number of T-cell antigens are differentially expressed in chronic lung disease patients depending on the prognosis of the patient. Non-limiting examples of these antigens include CD28, CD4, CD25, CD45, CD27 and CCR7 and combinations thereof. Use of these biomarker antigens, optionally in conjunction with pulmonary function tests, provides an indication of which patients are likely to suffer a severely adverse outcome within the year and/or be refractory to treatment. | 03-05-2015 |
20150064725 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF - Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful for production of proteins. | 03-05-2015 |
20150093766 | DIAGNOSTIC REAGENTS - There is provided a diagnostic reagent useful to determine whether an animal has a tuberculosis infection or has been exposed to a tuberculosis agent, for example a | 04-02-2015 |
20150125880 | METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC REGULATORY T CELLS - The present invention relates to methods to elicit immature antigen-presenting cells loaded with apoptotic cells or apoptotic bodies. The present invention also relates to methods of obtaining antigen-specific regulatory T cells in vitro or in vivo. Cells loaded with apoptotic bodies/cells and regulatory T cells are obtainable by inducing apoptosis of antigen-presenting cells by cytolytic CD4+ T cells. The cells are used for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are the use of antigen-specific regulatory T cells for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are populations of antigen-specific regulatory T cells obtained by said method. | 05-07-2015 |
20150125881 | METHODS OF ASSESSING THE IMMUNOMODULATORY POTENTIAL OF A MULTIPOTENT STROMAL CELL (MSC) POPULATION, AND SYSTEMS AND KITS FOR PRACTICING THE SAME - Methods of assessing the immunomodulatory potential of a multipotent stromal cell (MSC) population are provided. Aspects of the methods include evaluating the amount of CD54/IL-6 associated with an MSC in a sample of the MSC population to obtain a CD54/IL-6 result and providing an assessment of the immunomodulatory potential of the MSC population based on the obtained CD54/IL-6 result. Also provided are systems and kits that find use in practicing the subject methods. | 05-07-2015 |
20150125882 | MICROFLUIDIC DEVICES, AND METHODS OF MAKING AND USING THE SAME - The present disclosure provides methods and systems for assaying a sample. A microfluidic device to perform an assay of a sample (e.g., biological sample) is described having a sample application site, a porous component and a flow channel. The porous component provides for uniform dissolution of a reagent and mixing of the sample and reagent without filtering the sample. | 05-07-2015 |
20150132776 | KITS, COMPOSITIONS AND METHODS FOR DETECTING A BIOLOGICAL CONDITION - The present invention provides kits, apparatus and methods for determining a biological condition in a mammalian subject, the method includes incubating a specimen from a patient with at least one composition in a kit for a predetermined period of time to form at least one reaction product, when the subject has said biological condition, and receiving an indication of the at least one reaction product responsive to at least one reporter element in the kit thereby providing the indication of the biological condition in the subject. | 05-14-2015 |
20150140577 | OPTICAL ENGINE FOR FLOW CYTOMETER, FLOW CYTOMETER SYSTEM AND METHODS OF USE - An optical engine for use in a bench top flow cytometer, the optical engine comprising a set of lasers; a different set of beam shaping optics for each laser, wherein each set comprises two lenses to adjustably focus light horizontally along an x-axis to a same horizontal position and vertically along a y-axis to a different vertical position along a same plane; collection optics for collecting fluorescence from the flow cell; filtration optics that filter the collected fluorescence from the flow cell into different detection channels according to wavelength ranges; and a detector for each detection channel that converts the filtered fluorescence to electrical signals, wherein electrical signals are processed so that the fluorescence from each laser at the different vertical positions is distinguished at the same detector. | 05-21-2015 |
20150293095 | SYSTEMS AND METHODS FOR DETECTING A BIOLOGICAL CONDITION - The present invention provides self-contained systems, apparatus and methods for determining a chemical state, the system includes a stationary cartridge for performing the assay therein, the cartridge adapted to house at least one reagent adapted to react with a sample; and at least one reporter functionality adapted to report a reaction of the at least one reagent with the sample to report a result of the assay, a mechanical controller including a first urging means adapted to apply a force externally onto the cartridge to release the at least one reagent; and at least one second urging means adapted to apply a removable force to induce fluidic movement in a first direction in the cartridge and upon removal of the force causing fluidic movement in an opposite direction to the first direction, an optical reader adapted to detect the reaction and a processor adapted to receive data from the optical reader and to process the data to determine said chemical state. | 10-15-2015 |
20150299315 | NON-B-LINEAGE CELLS CAPABLE OF PRODUCING ANTIBODY - Disclosed herein are methods of identifying and methods of isolating antibody-producing cells and cells capable of producing antibodies, including V cells, a non-B-cell-lineage class of cells capable of producing antibody. Disclosed herein are kits for detection and isolation of antibody-producing cells and cells capable of producing antibodies. Disclosed herein are methods of making antibodies. | 10-22-2015 |
20150301044 | Peptide MHCII Tetramers to Detect Endogenous Calnexin Specific CD4 T Cells - The present application discloses proteins or peptides and methods of using such proteins or peptides to evaluate the immune status of a patient. In one embodiment, proteins or peptides may be used to detect endogenous calnexin specific CD4 T cells. In one preferred embodiment, the proteins or peptides may comprise peptide-MHCII tetramers (pMHC tetramers). | 10-22-2015 |
20150309049 | SYSTEMS AND METHODS FOR DETERMINING A CHEMICAL STATE - The present invention provides self-contained systems for performing an assay for determining a chemical state, the system including a stationary cartridge for performing the assay therein, at least one reagent adapted to react with a sample; and at least one reporter functionality adapted to report a reaction of the at least one reagent with said sample to report a result of the assay, wherein the at least one reagent, the sample and the at least one reporter functionality are contained within the cartridge. | 10-29-2015 |
20150330972 | CELL MEDIATED IMMUNE RESPONSE ASSAY - This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity which is achieved by adding a non-reducing sugar during incubation of the sample with the antigen. | 11-19-2015 |
20150338407 | ELISPOT METHOD HAVING TWO FILTER SYSTEMS - An ELISPOT method of in vitro diagnosis of tuberculosis includes enriching or separating liquid blood fraction from its cellular components including visualizing immunocompetent cells by detecting different dyes and using at least two different filter sets, each including one narrowband excitation filter and one narrowband blocking filter, wherein the narrowband excitation filter is transmissive for light provided for luminescent excitation of a respective dye and the narrowband blocking filter is transmissive for light emitted by a respective dye and measuring the number of immunocompetent cells that secrete at least interferon-γ and interleukin-2 as a reaction to an antigen by superimposing at least two two-dimensional images generated during visualization to avoid luminescence of different dyes interfering and strong luminescence being superimposed on weak luminescence. | 11-26-2015 |
20150377867 | MULTIPARAMETRIC METHOD FOR ASSESSING IMMUNE SYSTEM STATUS - The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event. | 12-31-2015 |
20160041164 | ANTI-LYMPHOCYTE AUTOANTIBODIES AS DIAGNOSTIC BIOMARKERS - Provided are methods, systems, and kits for diagnosing or monitoring systemic lupus erythematosus in an individual. In particular aspects, in a blood sample containing white blood cells from the individual, autoantibodies deposited on or contacting with the surface of a T lymphocyte in the sample are quantitated. | 02-11-2016 |
20160047809 | IMMUNOGENIC ANTIGENS FROM ASPERGILLUS FUMIGATUS - The present invention provides the in-vitro use of at least one in-vivo-target antigen of | 02-18-2016 |
20160061711 | APPARATUS AND METHODS FOR CELLULAR ANALYSIS - Disclosed are apparatus and methods for analyzing bodily fluids, such as blood samples, using an integrated hematology analyzer and flow cytometer system. Under the present approach, an integrated system may operate as a closed fluidic system or an open fluidic system, and may selectively perform automated hematologic protocols, flow cytometer protocols, and custom protocols. Such apparatus may, for example, identify and enumerate multiple cell types in whole blood based on cellular morphology, analyze cellular immunoassays using antibodies labeled to cells, and also detect low abundant analytes in whole blood as well as serum and other bodily fluids not attached to cells using bead-based immunoassay methods. The system may include a fluid handling system to control sample flow, an optical transducer that includes a flow cell, optical detectors for light scatter and/or fluorescence, and also an illumination source. | 03-03-2016 |
20160069878 | SEMI-AUTOMATED WHOLE BLOOD IMMUNO-POTENCY ASSAY - The present invention relates to a rapid, semi-automated whole blood assay to quantify the potency of cultured stem cells and biologicals in inhibiting monocyte and inducing T cell activation. Such an assay allows the quantification of the anti-inflammatory potency of therapeutic stem cell products for individual patients. | 03-10-2016 |
20160084828 | AUTOMATABLE METHOD FOR THE IDENTIFICATION, QUANTIFICATION AND DISCRIMINATION OF SPECIFIC SIGNALS IN RELATION TO NON-SPECIFIC SIGNALS IN DETECTION METHODS BY MEANS OF A DETECTOR - The invention relates to an automatable method for the identification, quantification and discrimination of specific signals in relation to non-specific signals in detection methods by means of a detector emitting or generating signals, in which at least one control approach is carried out in parallel to the actual test approach, which contains all the components of the actual test approach but in which the binding domain(s) of the detector is/are blocked. The analytical measurements of the signals of the control approach and of the actual test approach are compared with each other and the signal of the specifically bound detector in the test approach is calculated therefrom. | 03-24-2016 |
20160091492 | METHOD FOR THE DETECTION, PREPARATION AND DEPLETION OF CD4+ T LYMPHOCYTES - The present invention relates an in vitro method for detecting class II restricted CD4+ T cells in a sample. Herein a sample is contacted with an isolated complex of an MHC class II molecule and a peptide. This peptide comprises an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif. CD4+ T cells are detected by measuring the binding of the complex with cells in the sample, wherein the binding of the complex to a cell is indicative for the presence of CD4+ T cells in the sample. The present invention further relates to an isolated complex of an MHC Class II molecule and a peptide comprising an MHC class II restricted T cell epitope of an antigenic protein and immediately adjacent thereof, or separated by a linker of at most 7 amino acids a sequence with a [CST]-xx-C or C-xx-[CST] motif. | 03-31-2016 |
20160122402 | RETRO POLYPEPTIDES FOR ACTIVATION IMMUNITY TO CANCER AND VIRAL INFECTION - A polypeptide that drives T cell proliferation and differentiation, and methods and agents for modulating the expression and/or function of the polypeptide. Agents that up regulate the expression and/or function of the polypeptide are useful in the treatment or prevention of diseases and disorders that would benefit from stimulation of T cell proliferation and/or differentiation, such as cancer and chronic viral infections. Agents that down-regulate the expression and/or function of the polypeptide are useful in the treatment or prevention of diseases, disorders and conditions involving unwanted or excessive proliferation and/or differentiation of T cells, such as autoimmune and inflammatory diseases. Isolated T cells containing an expression vector encoding a polypeptide is also disclosed. Such T cells may be used in adoptive cell transfer therapies. | 05-05-2016 |
20160130343 | ANTI-ILT7 ANTIBODY - An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFNα. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFNα. | 05-12-2016 |
20160131646 | DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS - Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand. | 05-12-2016 |
20160139117 | METHOD FOR PREDICTING POST-THERAPY PROGNOSIS OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENT, AND METHOD FOR DETERMINING APPLICABILITY OF NOVEL THERAPY - According to the present invention, the amount of a plasmablast (PB) in a sample of a relapsing-remitting multiple sclerosis (RRMS) patient can be measured, thereby predicting the therapeutic effect of interferon beta (IFN-β) or predicting a RRMS case for which the continuous administration of IFN-β is difficult due to the manifestation of a serious adverse reaction or the aggravation of concomitant immune disorder. In addition, the amount of PB in a sample of a RRMS patient can also be measured, thereby predicting the therapeutic effect of an IL-6 inhibitor in the treatment of RRMS. As a result, a treatment method effective for patients not suitable for IFN-β in the treatment of RRMS can be provided. | 05-19-2016 |
20160146839 | METHODS FOR THE CLASSIFICATION AND DIAGNOSIS OF SCOLIOSIS THROUGH THE USE OF GI PROTEIN RECEPTOR - Methods for diagnosing a predisposition to developing a scoliosis (e.g., adolescent idiopathic scoliosis (AIS)) and identifying compounds for treating scoliosis based on the modulation of Gi protein-coupled receptor activity are described. Specific embodiments of the methods involve measuring a change in impedance signals of cells expressing a receptor coupled to a Gi protein with a ligand. To identify compounds useful in treatment, the cell is contacted with a test compound and a ligand. A higher impedance in the presence relative to the absence of said test compound is indicative that the test compound is useful for treating scoliosis. | 05-26-2016 |
20160153986 | PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS DIAGNOSTIC REAGENTS AND VACCINES | 06-02-2016 |
20160169888 | PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS DIAGNOSTIC REAGENTS AND VACCINES | 06-16-2016 |
20160169891 | METHODS AND KITS FOR IDENTIFYING EFFECTOR TREG CELLS | 06-16-2016 |
20160187241 | Method For Separating Cells Using Immunorosettes and Magnetic Particles - A concussive injury micronutrient formulation is provided and the formulation comprises vitamin A, vitamin E, natural mixed carotenoids, vitamin C, vitamin D, coenzyme Q10, alpha lipoic acid, N-acetyl cysteine, acetyl L-camitine (fumarate), vitamin B, folic acid, calcium, magnesium, selenium, chromium, biotin, zinc, and omega-3 fatty acids. The formulation is to be taken orally by humans and taken twice a day. | 06-30-2016 |
20160187326 | CELL DETECTION WITH CONJUGATES HAVING AN ENZYMATICALLY RELEASABLE DETECTION MOIETY - The invention is directed to a method for detecting a target moiety in a sample of biological specimens by:
| 06-30-2016 |
20160187336 | Microfluidic System and Method for Isolating and Quantifying at Least One Sub-Population of Cells From a Population of Cells - Disclosed are a microfluidic system ( | 06-30-2016 |
20160195530 | METHOD FOR ANALYSIS OF NKT CELL FUNCTION | 07-07-2016 |
20160251621 | SINGLE B-CELL CULTIVATION METHOD | 09-01-2016 |
20160252445 | DEVICES AND METHODS FOR MANIPULATING COMPONENTS IN A FLUID SAMPLE | 09-01-2016 |
20190145975 | METHOD TO IDENTIFY ANTIGEN-SPECIFIC IMMUNE CELLS | 05-16-2019 |